MK-8189 is a selective phosphodiesterase 10A inhibitor being developed for schizophrenia. It is developed by Merck in collaboration with Royalty Pharma. See also…
MK-8189 is a selective phosphodiesterase 10A inhibitor being developed for schizophrenia. It is developed by Merck in collaboration with Royalty Pharma.
See also List of investigational antipsychotics List of investigational bipolar disorder drugs Balipodect Mardepodect
References
Gebaseerd op: Wikipedia — MK-8189 · auteursgeschiedenis.
Tekst: CC BY-SA 4.0.
Wikisyntaxis en sjablonen zijn verwijderd; langere teksten zijn ingekort.